That is my understanding from talking to the mgt team. That is they can identify specific cells, target those specific cells and deliver a toxin using EET to 'kill' only the appropriate parts without affecting any of the surrounding cells or tissues.
Compared to the current efficacy and approach that sounds like a godsend to most cancer patients and could truly change the way cancer is treated around the world. At a stretch you could almost say it's getting as close to a cure as you can get without actually reversing or permanently removing the affliction.
I wonder what that could be worth on the open market?
...and then you start thinking about the other applications such as arthritis, alzheimers, etc... the mind boggles.
BUT, where I get concerned is that no external party has yet signed up to take it on-board as part of their program. Why not? Is there something we're all missing?
PYC Price at posting:
3.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)